Glen Eagle Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History
Bought
Maintained
Sold
Other funds holding BHVN
LIP
KCM
BC
BTI
FIA
IA
MSCM
Glen Eagle Advisors's BHVN Position: Q4 2022 in Review
Glen Eagle Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 33 shares — an estimated $4.99K sold.
Glen Eagle Advisors first reported a position in BHVN in Q3 2022 and held it in 1 quarter. The position peaked at $4.99K in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.
- Glen Eagle Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
- Glen Eagle Advisors sold 33 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $4.99K.
- Glen Eagle Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2022 and held it in 1 quarter.
- Glen Eagle Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $4.99K in Q3 2022.
- 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.
Based on Glen Eagle Advisors's 13F filing for Q4 2022, filed 13 Aug 2024.